Psychemedics Co. (NASDAQ:PMD) Major Shareholder Acquires $19,355.07 in Stock

Psychemedics Co. (NASDAQ:PMD) major shareholder Powell Anderson Capital Partne bought 7,473 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was bought at an average price of $2.59 per share, with a total value of $19,355.07. Following the completion of the purchase, the insider now directly owns 415,038 shares in the company, valued at $1,074,948.42. This represents a 1.83 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Powell Anderson Capital Partne also recently made the following trade(s):

• On Thursday, December 12th, Powell Anderson Capital Partne acquired 75,000 shares of Psychemedics stock. The shares were bought at an average price of $2.67 per share, with a total value of $200,250.00.

Psychemedics Stock Performance

Shares of PMD stock opened at $2.67 on Friday. The business has a fifty day moving average of $2.37 and a 200 day moving average of $2.32. Psychemedics Co. has a 1 year low of $1.63 and a 1 year high of $3.93. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.59 and a quick ratio of 1.59. The firm has a market capitalization of $15.73 million, a price-to-earnings ratio of -5.24 and a beta of 0.65.

About Psychemedics

Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol.